Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly's orforglipron
Source: SeekingAlpha
2026-02-10 15:17:20 ET
More on Eli Lilly
- Eli Lilly: Positives Outweigh The Concerns
- Eli Lilly and Company 2025 Q4 - Results - Earnings Call Presentation
- Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript
- Eli Lilly to buy Orna Therapeutics for up to $2.4B in cash
- Eli Lilly expands partnership with Innovent to develop oncology, immunology drugs
Read the full article on Seeking Alpha
For further details see:
Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly's orforglipron
Jiangnan Group Ltd
NASDAQ: JNGHF
JNGHF Trading
0.0% G/L:
$8.10 Last:
1,000 Volume:
$8.10 Open:
